Be Biopharma vs Biconomy
Side-by-side comparison of AI visibility scores, market position, and capabilities
$274M total raised including $92M Series C with Bristol Myers Squibb. Phase 1/2 active for BE-101 in Hemophilia B. CRISPR-engineered B cells as continuous protein factories.
About
Be Biopharma uses CRISPR to engineer a patient's own B cells into continuous protein-secreting factories — a one-time treatment designed to replace lifelong enzyme replacement therapy for rare metabolic diseases. The company has raised $274 million in total financing including a $92 million Series C co-led by Nextech Invest and Bristol Myers Squibb, with ARCH Venture Partners as a continuing investor, and has an active Phase 1/2 trial (BeCoMe-9) for BE-101 in Hemophilia B.
Web3 authentication and account abstraction infrastructure enabling gasless transactions and simplified dApp onboarding; ERC-4337 implementation allows dApps to sponsor gas fees on behalf of users and accept ERC-20 token gas payment for mainstream-accessible wallet experiences.
About
Biconomy is a Web3 infrastructure platform focused on making decentralized applications usable by mainstream audiences who are not familiar with cryptocurrency gas mechanics. Its core product implements account abstraction via ERC-4337, allowing dApp developers to sponsor gas fees on behalf of users, accept gas payment in ERC-20 tokens instead of native currency, and batch multiple on-chain transactions into a single user action. These capabilities transform the user experience from one requiring native token balances and technical awareness into something closer to a conventional web application workflow.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.